Kane Biotech Expands Commercial Activities in the United States
MWN-AI** Summary
Kane Biotech Inc. (TSX-V:KNE), based in Winnipeg, Manitoba, has announced a significant expansion of its commercial activities in the United States. On February 19, 2026, the company revealed that it has entered into non-exclusive distribution and sales agreements for its revyve® Antimicrobial Wound Gel product line with Patient Care Medical, located in Austin, Texas, and Life Biologics from Lakewood, New Jersey. These products, which include the revyve® Antimicrobial Wound Gel and the revyve® Antimicrobial Wound Gel Spray, are FDA 510(k) cleared and approved by Health Canada.
The agreements mark a strategic step in Kane Biotech’s efforts to enhance its presence in targeted sales channels and geographic markets across the U.S. Life Biologics will focus on national distribution in advanced wound care, while Patient Care Medical will serve specific regions including Louisiana, Mississippi, and the Gulf Coast, targeting both in-hospital and mobile wound care facilities. Kane Biotech is preparing for initial shipments of these products, which aim to address the challenges associated with biofilms in wound healing, a significant factor in antibiotic resistance.
Dr. Robert Huizinga, Interim CEO at Kane Biotech, emphasized that expanding the company’s U.S. distribution network remains a key priority, as these agreements will support their commercialization objectives. The revyve® product line is designed to tackle biofilms and wound bacteria, representing a novel approach in wound care treatment. Stakeholders and interested parties can learn more about Kane Biotech through their website and social media channels.
MWN-AI** Analysis
Kane Biotech Inc.'s recent expansion into the U.S. market through distribution agreements signals a pivotal moment for the company and offers intriguing opportunities for investors. The non-exclusive agreements with Patient Care Medical and Life Biologics enhance Kane Biotech's distribution capabilities, significantly increasing its visibility in two critical geographic regions. Given the company's FDA-cleared and Health Canada approved revyve® Antimicrobial Wound Gel and Spray products, this move is strategically aligned with the growing demand for advanced wound care solutions, particularly in addressing biofilm-related complications that contribute to antibiotic resistance.
From a market perspective, the expansion into the United States, a leading market in wound care products, could lead to substantial revenue growth. The agreement with Life Biologics targets the national advanced wound care sector, while Patient Care Medical focuses on localized markets within the Gulf Coast, suggesting a well-rounded approach to market penetration. As initial shipments commence, Kane Biotech is on a trajectory that could enhance operational cash flow and investor sentiment.
However, potential investors should remain aware of the inherent risks associated with the company, including its early stage of development, reliance on strategic partnerships, and financial leverage. Despite these risks, Kane Biotech's focus on innovative solutions in wound care positions it favorably against larger competitors who may not have similar specialized products targeting biofilms.
In conclusion, while investing in Kane Biotech presents certain risks typical of a biotech firm, the recent commercial activities and regulatory clearances could signify a growth inflection point. As such, investors with an appetite for the biotech sector should consider Kane Biotech as a candidate for their portfolio, closely monitoring upcoming sales performance and market reception of its products.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for its revyve® Antimicrobial Wound Gel® product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ).
US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel
and revyve Antimicrobial Wound Gel Spray
These U.S. non-exclusive distribution and sales agreements expand our presence in targeted sales channels and geographic markets. Life Biologics distributes nationally in advanced wound care, while Patient Care Medical distributes within Louisiana, Mississippi and the Gulf Coast specializing in in-hospital and mobile wound care facilities. Preparations are underway for initial shipments in the near term.
“Expanding our U.S. distribution network remains a key priority for the Company,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “These agreements enhance our access to selected U.S. markets and support our near-term commercialization objectives.”
About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel, revyve® Antimicrobial Wound Gel Spray and revyve® Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.
Follow Kane
Website: kanebiotech.com
LinkedIn: https://www.linkedin.com/company/kanebiotech/
Presentations: https://kanebiotech.com/publications-posters/
For more information:
| Dr. Robert Huizinga Interim CEO Kane Biotech Inc. rhuizinga@kanebiotech.com (780) 970-1100 | Ray Dupuis Chief Financial Officer Kane Biotech Inc. rdupuis@kanebiotech.com (204) 298-2200 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0d1a42a4-d94c-4ef6-9d38-68980e2c1bf1
FAQ**
How do the distribution agreements with Patient Care Medical and Life Biologics impact Kane Biotech Inc. (KNBIF) revenue forecasts for 2026 and beyond?
What strategies is Kane Biotech Inc. (KNBIF) implementing to enhance market acceptance for the revyve® product line in the U.S.?
Can Kane Biotech Inc. (KNBIF) address potential risks associated with early-stage development and dependency on partners as mentioned in the press release?
What plans does Kane Biotech Inc. (KNBIF) have to improve its financial condition and reduce reliance on equity financing in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about Kane Biotech Inc. (OTC: KNBIF).
NASDAQ: KNBIF
KNBIF Trading
0.0% G/L:
$0.027 Last:
10,000 Volume:
$0.027 Open:
